Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
This an an open-label study to define the safety profile and the maximum tolerated dose and confirm the clinical effective dose of palifosfamide-tris given intravenously in combination with etoposide and carboplatin in a wide range of cancers which etoposide and carboplatin are normally given. Once the maximum dose of palifosfamide-tris is determined,a Phase II study using the 3 agents combined will begin.
Epistemonikos ID: 65619b5e94626e68524a9eec3f2891c2daee4a54
First added on: May 06, 2024